Literature DB >> 9812213

Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis.

V Askanas1, W K Engel.   

Abstract

We discuss the pathologic diagnostic criteria and review the major new advances related to seeking the pathogenic mechanism of sporadic inclusion-body myositis (s-IBM) and hereditary inclusion-body myopathy (h-IBM). A classification of the various h-IBM syndromes is also presented. The several forms of the h-IBMs have different genetic transmissions and probably different genetic defects. In neither s-IBM nor the h-IBMs are the sequential steps of the pathogenic cascade understood. Because s-IBM and the h-IBMs have a number of characteristic pathologic features in common, we postulate that their different causes trigger the same upstream aberration leading to a similar downstream cascade of pathologic events, which are ultimately responsible for the characteristic muscle-fiber degeneration. Muscle-biopsy and experimental evidence is given supporting our hypothesis that overexpression of beta-amyloid precursor protein within abnormal muscle fibers is an early upstream event causing the pathogenic cascade. We also present evidence supporting our concept that muscle aging and oxidative stress are important factors contributing to the s-IBM-specific muscle fiber destruction. Additionally, the intriguing parallels between the pathologic phenotype of IBM muscle fibers and Alzheimer's disease brain are summarized.

Entities:  

Mesh:

Year:  1998        PMID: 9812213     DOI: 10.1097/00002281-199811000-00005

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  21 in total

1.  Autoantibody profiles in the sera of European patients with myositis.

Authors:  R Brouwer; G J Hengstman; W Vree Egberts; H Ehrfeld; B Bozic; A Ghirardello; G Grøndal; M Hietarinta; D Isenberg; J R Kalden; I Lundberg; H Moutsopoulos; P Roux-Lombard; J Vencovsky; A Wikman; H P Seelig; B G van Engelen ; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

Review 2.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

3.  Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 4.  Imaging of muscle disorders in children.

Authors:  Karl Johnson; Penny J C Davis; J Katharine Foster; Janet E McDonagh; Clive A J Ryder; Taunton R Southwood
Journal:  Pediatr Radiol       Date:  2006-06-15

5.  Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice.

Authors:  V Askanas; W K Engel
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

Review 6.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

7.  Dominant hereditary inclusion-body myopathy gene (IBM3) maps to chromosome region 17p13.1.

Authors:  T Martinsson; N Darin; M Kyllerman; A Oldfors; B Hallberg; J Wahlström
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

8.  Expression of granulysin in polymyositis and inclusion-body myositis.

Authors:  K Ikezoe; S Ohshima; M Osoegawa; M Tanaka; K Ogawa; K Nagata; J-i Kira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

Review 9.  Distal myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.